GT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
GT BIOPHARMA, INC. (GTBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 525.00 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-03-06
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-12-31 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-12-31 was -2.42M shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-09-30 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-06-30 was 500.00K shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 525.00K shares, a 2149.84% increase from fiscal 2024.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 23.34K shares, a 72.00% decline from fiscal 2023.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 83.33K shares, a 63.08% increase from fiscal 2022.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 51.10K shares, a 83.11% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | 525.00K shares 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | 525.00K shares 10-Q/A · filed 2026-03-06 | |||||
| 2024-12-31 | 23.34K shares 10-K · filed 2026-03-02 | |||||
| 2023-12-31 | -2.42M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -2.42M shares derived: sum of 2 quarters · filed 2025-02-21 | -1.92M shares derived: sum of 3 quarters · filed 2025-02-21 | 83.33K shares 10-K · filed 2025-02-21 | ||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | 500.00K shares derived: sum of 2 quarters · filed 2023-11-01 | 2.50M shares 10-Q · filed 2023-11-01 | 1.02M shares derived: sum of 4 quarters · filed 2024-03-26 | ||
| 2023-06-30 | 500.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 2.50M shares 10-Q · filed 2023-08-07 | 1.02M shares derived: sum of 3 quarters · filed 2024-03-26 | |||
| 2023-03-31 | 2.00M shares 10-Q · filed 2023-05-15 | 518.15K shares derived: sum of 2 quarters · filed 2024-03-26 | ||||
| 2022-12-31 | -1.48M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 51.10K shares 10-K · filed 2024-03-26 | 1.53M shares 10-K · filed 2023-03-30 | |||
| 2022-09-30 | 1.53M shares 10-Q · filed 2022-10-31 | |||||
| 2021-12-31 | 302.50K shares 10-K · filed 2023-03-30 | |||||
| 2021-02-16 | 4.38M shares 10-Q/A · filed 2021-12-29 | |||||
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-13 | 0.00 shares 10-Q · filed 2020-11-13 | |||
| 2020-06-30 | 0.00 shares derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-18 | 0.00 shares 10-Q/A · filed 2020-08-18 | ||||
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-15 | |||||
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | 0.00 shares 10-Q · filed 2020-11-13 | ||||
| 2019-06-30 | 0.00 shares 10-Q/A · filed 2020-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |